379 related articles for article (PubMed ID: 38389121)
1. Immunotherapy resistance in solid tumors: mechanisms and potential solutions.
Lefler DS; Manobianco SA; Bashir B
Cancer Biol Ther; 2024 Dec; 25(1):2315655. PubMed ID: 38389121
[TBL] [Abstract][Full Text] [Related]
2. Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition.
Kim HJ; Cantor H; Cosmopoulos K
Trends Immunol; 2020 Oct; 41(10):948-963. PubMed ID: 32976740
[TBL] [Abstract][Full Text] [Related]
3. Exploiting innate immunity for cancer immunotherapy.
Yi M; Li T; Niu M; Mei Q; Zhao B; Chu Q; Dai Z; Wu K
Mol Cancer; 2023 Nov; 22(1):187. PubMed ID: 38008741
[TBL] [Abstract][Full Text] [Related]
4. Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy.
Grisaru-Tal S; Rothenberg ME; Munitz A
Nat Immunol; 2022 Sep; 23(9):1309-1316. PubMed ID: 36002647
[TBL] [Abstract][Full Text] [Related]
5. Innate Immunity in Cancer Biology and Therapy.
Zhang Y; Xue W; Xu C; Nan Y; Mei S; Ju D; Wang S; Zhang X
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37510993
[TBL] [Abstract][Full Text] [Related]
6. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
7. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
8. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
Datta M; Coussens LM; Nishikawa H; Hodi FS; Jain RK
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():165-174. PubMed ID: 31099649
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
Saleh R; Elkord E
Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
[TBL] [Abstract][Full Text] [Related]
10. Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors.
Kalkusova K; Smite S; Darras E; Taborska P; Stakheev D; Vannucci L; Bartunkova J; Smrz D
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232398
[TBL] [Abstract][Full Text] [Related]
11. Mechanism and strategies of immunotherapy resistance in colorectal cancer.
Shan J; Han D; Shen C; Lei Q; Zhang Y
Front Immunol; 2022; 13():1016646. PubMed ID: 36238278
[TBL] [Abstract][Full Text] [Related]
12. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
13. Editorial: The intricate innate immune-cancer cell relationship in the context of tumor angiogenesis, immunity and microbiota: The angiogenic switch in the tumor microenvironment as a key target for immunotherapies.
Mortara L; Benest AV; Derosa L; Chouaib S; Ribatti D
Front Immunol; 2022; 13():1045074. PubMed ID: 36275734
[No Abstract] [Full Text] [Related]
14. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
Front Immunol; 2021; 12():777073. PubMed ID: 34868044
[TBL] [Abstract][Full Text] [Related]
15. Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors.
Sedky NK; Hamdan AA; Emad S; Allam AL; Ali M; Tolba MF
Clin Transl Oncol; 2022 Jul; 24(7):1262-1273. PubMed ID: 35066777
[TBL] [Abstract][Full Text] [Related]
16. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
17. The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance.
Cerezo M; Robert C; Liu L; Shen S
Cancer Res; 2021 Nov; 81(22):5596-5604. PubMed ID: 34470777
[TBL] [Abstract][Full Text] [Related]
18. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy.
Jin Z; Sun X; Wang Y; Zhou C; Yang H; Zhou S
Front Immunol; 2022; 13():1018903. PubMed ID: 36300110
[TBL] [Abstract][Full Text] [Related]
19. Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment.
Kirchhammer N; Trefny MP; Auf der Maur P; Läubli H; Zippelius A
Sci Transl Med; 2022 Nov; 14(670):eabo3605. PubMed ID: 36350989
[TBL] [Abstract][Full Text] [Related]
20. Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities.
Bashash D; Zandi Z; Kashani B; Pourbagheri-Sigaroodi A; Salari S; Ghaffari SH
J Cell Physiol; 2022 Jan; 237(1):346-372. PubMed ID: 34498289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
